FrancophonIA/ELRC3.0 huggingface dataset:
English: d The Overall p-value is based on a Cochran-Mantel-Haenszel test; the nominal p-value for the with clobazam subgroup is based on logistic regression analysis.
Croatian: d Ukupna p-vrijednost temelji se na testu Cochran-Mantel-Haenszel; nominalna p-vrijednost za podskupine s klobazamom temelji se na analizi logističke regresije.
English: In vivo assessment of drug interactions
Croatian: In vivo procjena interakcija lijekova
English: Approximately 50% of the patients were taking concomitant clobazam.
Croatian: Oko 50% bolesnika istovremeno je uzimalo klobazam.
English: No adverse reactions were observed on male or female fertility or reproduction performance in rats at doses up to 250 mg/kg/day (approximately 60-fold greater than the maximum recommended human dose (MRHD) at 20 mg/kg/day).
Croatian: Nisu uočene nuspojave vezane uz plodnost muških ili ženskih štakora, kao ni na reproduktivnu sposobnost pri dozama do 250 mg/kg/dan (oko 60 puta više nego u ljudi pri maksimalnoj preporučenoj dozi za ljude (engl. maximum recommended human dose, MRHD) od 20 mg/kg/dan).
English: In controlled trials (see section 5.1) in patients taking cannabidiol 20 mg/kg/day, the frequency of treatment-emergent ALT elevations greater than 3 times the ULN was 31% (84% of these were on valproate) when ALT was above the ULN at baseline, compared to 12% (89% of these were on valproate) when ALT was within the normal range at baseline.
Croatian: U kontroliranim ispitivanjima (vidjeti dio 5.1) u bolesnika koji uzimaju kanabidiol u dozi od 20 mg/kg/dan, učestalost povišenja ALT-a povezanih s liječenjem većih od 3 puta GGN bila je 31% (84% njih je bilo na valproatu) kad je ALT bio iznad gornje granice normalnih vrijednosti (GGN) na početku, u odnosu na 12% (89% njih je bilo na valproatu) kad je ALT bio unutar normalnih granica na početku.
English: Placebo 10 mg/kg/day 20 mg/kg/day
Croatian: Placebo 10 mg/kg/dan 20 mg/kg/dan
English: d The Overall p-value is based on a Cochran-Mantel-Haenszel test; the nominal p-values for the with clobazam subgroup are based on logistic regression analysis.
Croatian: d Ukupna p-vrijednost se temelji se na testu Cochran-Mantel-Haenszel; nominalne p-vrijednosti za podskupine s klobazamom temelje se na analizi logističke regresije.
English: No effects on cannabidiol or metabolite exposures were observed following administration of a single dose of cannabidiol 200 mg in subjects with mild hepatic impairment.
Croatian: Nisu uočeni učinci na izloženost kanabidiolu ili metabolitima nakon primjene jedne doze kanabidiola od 200 mg u ispitanika s blagim oštećenjem funkcije jetre.
English: Signs of taking more Epidyolex than you should include diarrhoea and sleepiness.
Croatian: Znakovi predoziranja Epidyolexom uključuju proljev i pospanost.
English: The frequency in patients receiving 10 mg/kg/day cannabidiol and taking clobazam was 36%.
Croatian: Učestalost u bolesnika koji su primali 10 mg/kg/dan kanabidiola i uzimali klobazam bila je 36%.
English: Frequency Adverse reactions from clinical trials
Croatian: Nuspojave iz kliničkih ispitivanja
English: Concomitant use of cannabidiol and valproate increases the incidence of transaminase enzyme elevations (see section 4.4).
Croatian: Istovremena primjena kanabidiola i valproata povećava incidenciju povišenja enzima transaminaza (vidjeti dio 4.4).
English: The frequency in patients receiving 20 mg/kg/day cannabidiol and taking clobazam was 41%.
Croatian: Učestalost u bolesnika koji su primali 20 mg/kg/dan kanabidiola i uzimali klobazam bila je 41%.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of oral solution contains 100 mg cannabidiol.
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Jedan ml oralne otopine sadrži 100 mg kanabidiola.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with cannabidiol in one or more subsets of the paediatric population in treatment of seizures associated with DS and LGS.
Croatian: Europska agencija za lijekove je odgodila obvezu podnošenja rezultata ispitivanja s kanabidiolom na jednoj ili više podskupina pedijatrijske populacije u liječenju napadaja povezanih sa stanjima DS i LGS (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Epidyolex contains sesame oil, alcohol (ethanol), strawberry flavour components (including benzyl alcohol).
Croatian: Epidyolex sadrži sezamovo ulje, alkohol (etanol), komponente za okus jagode (uključujući benzilni alkohol).
English: Adjunctive Therapy in Patients with Dravet Syndrome The efficacy of cannabidiol for the adjunctive therapy of seizures associated with Dravet syndrome (DS) was evaluated in two randomised, double-blind, placebo-controlled, parallel-group studies (GWPCARE2 and GWPCARE1).
Croatian: Dodatna terapija u bolesnika sa Dravetovim sindromom Djelotvornost kanabidiola za dodatnu terapiju napadaja povezanih sa Dravetovim sindromom (DS) je procijenjena u dva randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja s paralelnim skupinama (GWPCARE2 i GWPCARE1).
English: The most commonly used cAEDs (> 25% of patients) in both trials were valproate, clobazam, stiripentol, and levetiracetam.
Croatian: Najčešće istovremeno primjenjivani antiepileptici (> 25% bolesnika) u oba ispitivanja su bili valproat, klobazam, stiripentol i levetiracetam.
English: Cannabidiol should be discontinued in any patients with elevations of transaminase levels greater than 3 times the ULN and bilirubin levels greater than 2 times the ULN.
Croatian: Primjenu kanabidiola bi trebalo prekinuti kod bolesnika s povišenjem razina transaminaza većim od 3 puta GGN i razinom bilirubina većom od 2 puta GGN.
English: Patients with baseline transaminase levels above the ULN had higher rates of transaminase elevations when taking cannabidiol.
Croatian: Bolesnici čije su početne vrijednosti razine transaminaza bile iznad GGN imali su više stope povišenja razina transaminaza dok su uzimali kanabidiol.
English: cannabidiol and/or concomitant AED treatment should therefore be adjusted during regular medical supervision and the patient should be closely monitored for adverse drug reactions.
Croatian: Zato se za vrijeme redovitog medicinskog nadzora mora prilagoditi doza kanabidiola i/ili istovremeno korištenog antiepileptika, a bolesnici se moraju pomno pratiti zbog nuspojava lijeka.
English: Patients with elevated baseline transaminase levels above 3 times the ULN, or elevations in bilirubin above 2 times the ULN, should be evaluated prior to initiation of cannabidiol treatment.
Croatian: Bolesnike čije su početne vrijednosti razine transaminaza bile više od 3 puta GGN ili sa povišenjem bilirubina višim od 2 puta GGN treba procijeniti prije početka liječenja kanabidiolom.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER GW Pharma (International) B.V., Databankweg 26, 3821AL Amersfoort, The Netherlands
Croatian: 11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET GW Pharma (International) B.V., Databankweg 26, 3821AL Amersfoort, Nizozemska
English: Concomitant use of cannabidiol and valproate increases the incidence of diarrhoea and events of decreased appetite.
Croatian: Istovremena primjena kanabidiola i valproata povećava incidenciju proljeva i smanjenog teka.
English: Resolution of transaminase elevations occurred with discontinuation of cannabidiol or reduction of cannabidiol and/or concomitant valproate in about two-thirds of the cases.
Croatian: S prekidom uzimanja kanabidiola ili smanjenjem doze kanabidiola i/ili istovremenog valproata riješen je problem povišenih transaminaza u otprilike dvije trećine slučajeva.
English: The metabolite 7-carboxy-cannabidiol (7-COOH-CBD) is an inhibitor of UGT1A1, UGT1A4 and UGT1A6-mediated activity, in vitro at clinically relevant concentrations (see also section 4.5).
Croatian: Metabolit 7-karboksikanabidiol (7-COOH-CBD) je inhibitor aktivnosti posredovane putem UGT1A1, UGT1A4 i UGT1A6, in vitro u klinički značajnim koncentracijama (vidjeti i dio 4.5).
English: Mean age of the study population was 15 years and 94% were taking 2 or more concomitant AEDs (cAEDs) during the trial.
Croatian: Srednja vrijednost dobi populacije u ispitivanju je bila 15 godina, a 94% ispitanika je tijekom ispitivanja uzimalo 2 ili više istovremenih antiepileptika.
English: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Croatian: Nuspojave su unutar pojedinih skupina učestalosti navedene u padajućem nizu prema ozbiljnosti.
English: The bottle is packaged in a carton with two 5 ml and two 1 ml calibrated oral dosing syringes (plunger HDPE and barrel polypropylene) and two bottle adapters (LDPE).
Croatian: Bočica je zapakirana u kartonsku ambalažu u kojoj se nalaze dvije dozirne štrcaljke za usta kalibrirane na 5 ml i dvije dozirne štrcaljke za usta kalibrirane na 1 ml (klip štrcaljke od polietilena visoke gustoće (HDPE) i cilindar štrcaljke od polipropilena), te dva adaptera za bočicu (LDPE).
English: • Epidyolex oral solution bottle
Croatian: • Bočica Epidyolex oralne otopine
English: Place the tip of the oral syringe inside the cheek, and gently push the plunger to release the medicine.
Croatian: Postavite vrh štrcaljke u usta, te nježno pritisnite klip kako biste ispustili lijek.
English: Amber glass bottle (type III) with a child-resistant and tamper-evident screw cap (polypropylene).
Croatian: Smeđa staklena bočica (tip III) sa zaštitnim zatvaračem s navojem sigurnim za djecu (polipropilen).
English: In vitro assessment of drug interactions
Croatian: In vitro procjena interakcija lijekova
English: Do not reduce the dose or stop taking Epidyolex without first talking to your doctor.
Croatian: Ako Vi ili bolesnik prestanete uzimati Epidyolex Nemojte smanjivati dozu ili prestati s uzimanjem Epidyolexa bez prethodnog razgovora sa svojim liječnikom.
English: • A plastic bag containing two 1 ml oral syringes and a bottle adaptor
Croatian: • Plastična vrećica s dvjema štrcaljkama za usta od 1 ml i adapterom za bočicu
English: Hepatocellular injury Cannabidiol causes dose-related elevations of ALT and AST (see section 4.4).
Croatian: Hepatocelularna ozljeda Kanabidiol uzrokuje povišenje ALT-a i AST-a povezano s dozom (vidjeti dio 4.4).
English: Cannabidiol is predominantly cleared by metabolism in the liver and gut and excreted in faeces, with renal clearance of parent drug being a minor pathway.
Croatian: Kanabidiol se uglavnom uklanja kroz metabolizam u jetri i crijevima, te izlučuje u stolici, uz manje izlučivanje ishodišnog lijeka putem bubrega.
English: Cannabidiol can cause decreases in haemoglobin and haematocrit.
Croatian: Kanabidiol može uzrokovati pad hemoglobina i hematokrita.
English: Lamotrigine levels may be elevated when it is co-administered with cannabidiol.
Croatian: Razine lamotrigina mogu porasti ako se primjenjuje zajedno s kanabidiolom.
English: Key secondary endpoints for GWPCARE2 were the proportion of patients with at least a 50% reduction in convulsive seizure frequency, the change in total seizure frequency, and Caregiver Global Impression of Change at the last visit.
Croatian: Ključne sekundarne mjere ishoda za GWPCARE2 su bile udio bolesnika s barem 50%-tnim smanjenjem učestalosti konvulzivnih napadaja, promjena u ukupnoj učestalosti napadaja, te globalni dojam promjene njegovatelja na zadnjem posjetu.
English: Subgroup analyses were conducted on multiple factors, including cAEDs.
Croatian: Analize podskupina provedene su s više faktora, uključujući istovremene antiepileptike.
English: In LGS and DS patients, the decrease in weight appeared to be dose-related, with 19% of patients on cannabidiol 20 mg/kg/day experiencing a decrease in weight ≥ 5%, compared to 8% in patients on cannabidiol 10 mg/kg/day.
Croatian: U bolesnika koji imaju LGS i DS čini se kako je smanjenje tjelesne težine povezano s dozom, s 19% bolesnika koji su uzimali kanabidiol u dozi od 20 mg/kg/dan koji su izgubili ≥ 5% tjelesne težine, u usporedbi sa 8% bolesnika koji su uzimali kanabidiol u dozi od 10 mg/kg/dan.
English: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, UGT1A9, and UGT2B7 Substrates In vitro data predict drug-drug interactions with CYP1A2 substrates (e.g., theophylline, caffeine), CYP2B6 substrates (e.g., bupropion, efavirenz), uridine 5' diphospho-glucuronosyltransferase 1A9 (UGT1A9) (e.g., diflunisal, propofol, fenofibrate), and UGT2B7 (e.g., gemfibrozil, morphine, lorazepam) when co-administered with cannabidiol.
Croatian: In vitro podaci predviđaju interakcije sa supstratima CYP1A2 (npr. teofilin, kofein), supstratima CYP2B6 (npr. bupropion, efavirenz), uridin-5'-difosfoglukuronoziltransferaza 1A9 (UGT1A9) (npr. diflunisal, propofol, fenofibrat) i UGT2B7 (npr. gemfibrozil, morfin, lorazepam) kad se primjenjuju zajedno s kanabidiolom.
English: Compared with placebo, cannabidiol was associated with an increase in the number of convulsive seizure-free days during the treatment period in each trial, equivalent to 2.7 days per 28 days (10 mg/kg/day) and 1.3 to 2.2 days per 28 days (20 mg/kg/day).
Croatian: U usporedbi s placebom, kanabidiol je povezan s povećanjem broja dana bez konvulzivnih napadaja tijekom razdoblja liječenja u svakom od ispitivanja; ekvivalentno 2,7 dana na 28 dana (10 mg/kg/dan) odnosno 1,3 do 2,2 dana na 28 dana (20 mg/kg/dan).
English: Package leaflet: Information for the patient Epidyolex 100 mg/ml oral solution cannabidiol
Croatian: Uputa o lijeku: Informacije za bolesnika Epidyolex 100 mg/ml oralna otopina kanabidiol
English: Because of potential inhibition of enzyme activity, dose reduction of substrates of UGT1A9, UGT2B7, CYP2C8, and CYP2C9 should be considered, as clinically appropriate, if adverse reactions are experienced when administered concomitantly with cannabidiol.
Croatian: Zbog moguće inhibicije aktivnosti enzima, treba razmotriti i smanjenje doze supstrata UGT1A9, UGT2B7, CYP2C8 i CYP2C9 prema kliničkoj situaciji, u slučaju nuspojava kod istovremene primjene s kanabidiolom.
English: Population pharmacokinetic analyses demonstrated that there were no clinically relevant effects of age, body weight, sex, or race on exposure to cannabidiol.
Croatian: Učinak dobi, tjelesne težine, spola, etničke pripadnosti Analiza populacijske farmakokinetike je pokazala kako nema klinički značajnih učinaka dobi, tjelesne težine, spola i etničke pripadnosti na izloženost kanabidiolu.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER GW Pharma (International) B.V., Databankweg 26
Croatian: 11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET GW Pharma (International) B.V., Databankweg 26
English: A pre- and post-natal development study was performed in rats at doses of 75, 150, or 250 mg/kg/day.
Croatian: Ispitivanje prenatalne i postnatalne razvojne toksičnosti u štakora provedeno je pri dozama od 75, 150 ili 250 mg/kg/dan.
English: In the subgroup of DS patients treated with concomitant clobazam for 37 to 48 weeks (N=54), the median percentage reduction from baseline in convulsive seizure frequency was 60% during Week 1-12, which was maintained through to Week 37-48, with a median percentage reduction from baseline in convulsive seizure frequency of 45%.
Croatian: U podskupini bolesnika koji imaju DS istovremeno liječenih klobazamom tijekom 37 do 48 tjedana (N = 54), medijan postotnog smanjenja učestalosti konvulzivnih napadaja u odnosu na početnu vrijednost bio je 60% tijekom 1. do 12. tjedna, što se održalo do 37. do 48. tjedna uz medijan postotnog smanjenja učestalosti konvulzivnih napadaja od 45%.
English: ALT elevations greater than 3 times the ULN were reported in 16% of patients taking cannabidiol 20 mg/kg/day compared with 3% in patients taking cannabidiol 10 mg/kg/day.
Croatian: Povišenja ALT-a veća od 3 puta GGN su prijavljena u 16% bolesnika koji uzimaju kanabidiol u dozi od 20 mg/kg/dan u usporedbi s 3% u bolesnika koji uzimaju kanabidiol u dozi od 10 mg/kg/dan.
English: In the subgroup of LGS patients treated with concomitant clobazam for 37 to 48 weeks (N=161), the median percentage reduction from baseline in drop seizure frequency was 71% during Week 1-12, which was maintained through to Week 37-48, with a median percentage reduction from baseline in drop seizure frequency of 63%.
Croatian: U podskupini bolesnika s LGS-om istovremeno liječenih klobazamom tijekom 37 do 48 tjedana (N = 161), medijan postotnog smanjenja učestalosti astatskih napadaja u odnosu na početnu vrijednost bio je 71% tijekom 1. do 12. tjedna, što se održalo do 37. do 48. tjedna uz medijan postotnog smanjenja učestalosti astatskih napadaja od 63% u odnosu na početnu vrijednost.
English: • If your dose is more than 5 ml (500 mg), you will need to use the larger 5 ml syringe more than once.
Croatian: • Ako je Vaša doza veća od 5 ml (500 mg), trebali biste upotrebljavati veću štrcaljku od 5 ml više od jedanput.
English: NAME OF THE MEDICINAL PRODUCT Epidyolex 100 mg/ml oral solution
Croatian: NAZIV LIJEKA Epidyolex 100 mg/ml oralna otopina
English: The 5 ml syringes are graduated in 0.1 ml and the 1 ml in 0.05 ml increments.
Croatian: Štrcaljke od 5 ml imaju oznake na svakih 0,1 ml, a štrcaljke od 1 ml na svakih 0,05 ml.
English: Metabolism and nutrition disorders
Croatian: Poremećaji metabolizma i prehrane Vrlo često
English: In vitro data suggest that cannabidiol is an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, UGT1A9 and UGT2B7-mediated activity at clinically relevant concentrations.
Croatian: In vitro podaci sugeriraju da je kanabidiol inhibitor aktivnosti posredovane putem CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, UGT1A9 i UGT2B7 u klinički značajnim koncentracijama.
English: 10 mg/kg/day, 62% to 77% on 20 mg/kg/day, 30% to 41% on placebo; p=0.0009 for 10 mg/kg/day and p=0.0018 and 0.0136 for 20 mg/kg/day vs. placebo).
Croatian: 62% do 77% na 20 mg/kg/dan, 30% do 41% na placebu; p = 0,0009 za 10 mg/kg/dan i p = 0,0018 i 0,0136 za 20 mg/kg/dan u usporedbi s placebom).
English: Table 5: Drug interactions between cannabidiol and concomitant antiepileptic drugs Concomitant AED Influence of AED on cannabidiol Influence of cannabidiol on AED Clobazam
Croatian: Tablica 5: Interakcije između kanabidiola i istovremeno primijenjenih antiepileptika
English: The metabolite 7-carboxy-cannabidiol (7-COOH-CBD) is also an inhibitor of UGT1A1, UGT1A4 and UGT1A6-mediated activity in vitro.
Croatian: Metabolit 7-karboksikanabidiol (7-COOH-CBD) je također inhibitor aktivnosti posredovane putem UGT1A1, UGT1A4 i UGT1A6 in vitro.
English: Table 3: Primary and ≥ 50% responder key secondary outcome measures and subgroup analysis in LGS studies
Croatian: Tablica 3: Primarne i ključne sekundarne mjere ishoda za bolesnike s ≥ 50% odgovorom i analize podskupina u LGS ispitivanjima
English: What Epidyolex looks like and contents of the pack Epidyolex is a clear, colourless to yellow oral solution.
Croatian: Epidyolex je prozirna, bezbojna do žuta oralna otopina.
English: Table 4 summarises the primary endpoint of percent reduction from baseline in convulsive seizures, and the key secondary measure of proportion of patients with at least a 50% reduction in convulsive seizure frequency, as well as results of the subgroup analysis for these outcome measures in patients treated with concomitant clobazam.
Croatian: Tablica 4 prikazuje sažetak primarne mjere ishoda postotnog smanjenja konvulzivnih napadaja u odnosu na početnu vrijednost i ključnu sekundarnu mjeru ishoda, udio bolesnika s najmanje 50% smanjenja učestalosti konvulzivnih napadaja, kao i rezultate analize podskupina za ove mjere ishoda u bolesnika istovremeno liječenih klobazamom.
English: Baseline transaminase elevations
Croatian: Povišenja početnih vrijednosti transaminaza
English: - Two 1 ml syringes graduated in 0.05 ml increments (each 0.05 ml increment corresponds to 5 mg cannabidiol) - Two 5 ml syringes graduated in 0.1 ml increments (each 0.1 ml increment corresponds to 10 mg cannabidiol)
Croatian: - dvjema štrcaljkama od 5 ml s oznakama na svakih 0,1 ml (svakih 0,1 ml odgovara količini od 10 mg kanabidiola)
English: A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer(s) responsible for batch release GW Pharma (International) B.V., Databankweg 26
Croatian: PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet GW Pharma (International) B.V., Databankweg 26
English: Discard unused portion 8 weeks after first opening Date of first opening:
Croatian: Preostali sadržaj baciti 8 tjedana nakon prvog otvaranja.
English: Refined sesame oil
Croatian: Rafinirano sezamovo ulje Bezvodni etanol
English: INFORMATION IN BRAILLE epidyolex
Croatian: 16. PODACI NA BRAILLEOVOM PISMU epidyolex
English: Compared with placebo, cannabidiol was associated with an increase in the number of drop seizure-free days during the treatment period in each trial, equivalent to 3.3 days per 28 days (10 mg/kg/day) and 5.5 to 7.6 days per 28 days (20 mg/kg/day).
Croatian: U usporedbi s placebom, kanabidiol je povezan s povećanjem broja dana bez astatskih napadaja tijekom razdoblja liječenja u svakom od ispitivanja; ekvivalentno 3,3 dana na 28 dana (10 mg/kg/dan) odnosno 5,5 do 7,6 na 28 dana (20 mg/kg/dan).
English: Patients with sustained transaminase elevations of greater than 5 times the ULN should also have treatment discontinued.
Croatian: Bolesnici s neprekidno povišenim transaminazama većim od 5 puta GGN također trebaju prestati s uzimanjem kanabidiola.
English: Data for study GWPCARE2 and the with clobazam subgroup are presented as percent reduction from baseline estimated from a negative binomial regression analysis.
Croatian: Podaci za ispitivanje GWPCARE2 i podskupine sa klobazamom predstavljeni su kao postotno smanjenje u odnosu na početak procijenjeno analizom negativne binomne regresije.
English: Interaction resulting in an increase in exposure of the active metabolite 7-OH-CBD in HV* studies.
Croatian: Interakcija koja dovodi do porasta izloženosti aktivnom metabolitu 7-OH-CBD u ispitivanjima na zdravim dobrovoljcima.a
English: Table 4: Primary and ≥ 50% responder key secondary outcome measures and subgroup analysis in DS studies
Croatian: Tablica 4: Primarne i ključne sekundarne mjere ishoda za bolesnike s ≥ 50% odgovorom i analize podskupina u DS ispitivanjima
English: LIST OF EXCIPIENTS Contains refined sesame oil, ethanol and strawberry flavour components (including benzyl alcohol).
Croatian: POPIS POMOĆNIH TVARI Sadrži rafinirano sezamovo ulje, etanol i komponente za okus jagode (uključujući benzilni alkohol).
English: • If your dose is 1 ml (100 mg) or less, you should use the smaller 1 ml syringe.
Croatian: • Ako je Vaša doza 1 ml (100 mg) ili manja, trebali biste upotrebljavati manju štrcaljku od
English: Table 3 summarises the primary endpoint of percent reduction from baseline in drop seizures, and the key secondary measure of proportion of patients with at least a 50% reduction in drop seizure frequency, as well as results of the subgroup analysis for these outcome measures in patients treated with concomitant clobazam.
Croatian: Tablica 3 prikazuje sažetak primarne mjere ishoda postotnog smanjenja astatskih napadaja u odnosu na početak i ključnu sekundarnu mjeru ishoda, udio bolesnika s najmanje 50% smanjenja učestalosti astatskih napadaja, kao i rezultate analize podskupina za ove mjere ishoda u bolesnika istovremeno liječenih klobazamom.
English: Each ml of oral solution contains 100 mg of cannabidiol.
Croatian: Jedan ml oralne otopine sadrži 100 mg kanabidiola.
English: GWPCARE4 Placebo 20 mg/kg/day p=0.0043
Croatian: GWPCARE4 Placebo 20 mg/kg/dan p = 0,0043
English: Key secondary endpoints were the proportion of patients with at least a 50% reduction in drop seizure frequency, the percentage change from baseline in total seizure frequency, and Subject/Caregiver Global Impression of Change at the last visit.
Croatian: Ključne sekundarne mjere ishoda su bile udio bolesnika s barem 50%-nim smanjenjem učestalosti astatskih napadaja, postotna promjena u odnosu na početak u ukupnoj učestalosti napadaja, te globalni dojam promjene ispitanika/njegovatelja na zadnjem posjetu.